About
Bigfoot Biomedical is a medical technology company based in Milpitas, California, dedicated to enhancing diabetes care for individuals with insulin-dependent diabetes, including type 1 and type 2 diabetes. Founded by a team with personal ties to diabetes, the company focuses on simplifying insulin therapy through innovative, connected solutions. In September 2023, Bigfoot Biomedical was acquired by Abbott Laboratories, which strengthens its role in diabetes management technology. The company develops automated insulin delivery systems and smart insulin pen solutions. The Bigfoot Loop is a closed-loop system that integrates a Bluetooth-enabled insulin pump with Abbott’s FreeStyle Libre continuous glucose monitoring system and a smartphone app to automate insulin dosing. The Bigfoot Inject is a Bluetooth-connected smart insulin pen designed for users of multiple daily injections, also integrating with CGM technology. Additionally, the Bigfoot Unity Diabetes Management Program supports insulin dosing decisions through smart pen caps and the FreeStyle Libre 2 CGM platform. Bigfoot Biomedical aims to provide comprehensive, user-friendly solutions for a broad range of insulin-dependent patients.
Technologies
Keywords
Company Information
-
Employees 63
-
Founded 2014
-
Annual Revenue $25000000
-
Total Funding $204500000
Location
1820 McCarthy Blvd, Milpitas, California, United States, 95035